Granules India has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 22.40% fall in its net profit at Rs 97.22 crore for the quarter under review as compared to Rs 125.29 crore for the same quarter in the previous year. Total income of the company decreased by 7.16% at Rs 943.62 crore for Q4FY24 as compared Rs 1,016.44 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 8.39% rise in its net profit at Rs 129.65 crore for fourth quarter ended March 31, 2024 as compared to Rs 119.61 crore for the same quarter in the previous year. However, total income of the company decreased by 1.77% at Rs 1,177.65 crore for Q4FY24 as compared Rs 1,198.88 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 12.60% fall in its net profit at Rs 435.92 crore as compared to Rs 498.79 crore for the previous year. Total income of the company decreased by 4.57% at Rs 3,760.87 crore for year under review as compared to Rs 3,941.13 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 21.54% fall in its net profit at Rs 405.31 crore as compared to Rs 516.60 crore for the previous year. Total income of the company decreased by 0.33% at Rs 4,510.77 crore for year under review as compared to Rs 4,525.70 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1489.65 |
Dr. Reddys Lab | 5992.15 |
Cipla | 1490.00 |
Zydus Lifesciences | 1044.50 |
Lupin | 1603.25 |
View more.. |